IMPL Impel NeuroPharma Inc.

13.89
+0.27  (+2%)
Previous Close 13.62
Open 13.46
52 Week Low 13.5
52 Week High 15.89
Market Cap $269,672,044
Shares 19,414,834
Float 7,013,183
Enterprise Value $265,746,039
Volume 17,818
Av. Daily Volume 0
Stock charts supplied by TradingView

Upcoming Catalysts

Drug Stage Catalyst Date
INP104 (Dihydroergotamine)
Migraine
PDUFA
PDUFA
Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 14-day FREE TRIAL.
INP105 (Olanzapine)
Acute Agitation
Phase 2
Phase 2
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.

Drug Pipeline

Drug Stage Notes
INP107 (Levodopa/Carbidopa)
Morning OFF Episodes in Parkinson’s
Phase 1
Phase 1
Phase 1 trial completed. PK study for pivotal dose selection to be initiated in 2022.

Latest News

  1. SEATTLE, April 22, 2021 (GLOBE NEWSWIRE) -- Impel NeuroPharma, Inc. (Impel), a late-stage pharmaceutical company focused on utilizing its proprietary technology to develop and commercialize transformative therapies for patients suffering from diseases with high unmet medical needs, today announced the pricing of its initial public offering of 5,333,334 shares of its common stock at a price to the public of $15.00 per share. All of the shares are being offered by Impel. The shares are expected to begin trading on The Nasdaq Global Market on April 23, 2021 under the symbol "IMPL." The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Impel, are expected to be $80.0…

    SEATTLE, April 22, 2021 (GLOBE NEWSWIRE) -- Impel NeuroPharma, Inc. (Impel), a late-stage pharmaceutical company focused on utilizing its proprietary technology to develop and commercialize transformative therapies for patients suffering from diseases with high unmet medical needs, today announced the pricing of its initial public offering of 5,333,334 shares of its common stock at a price to the public of $15.00 per share. All of the shares are being offered by Impel. The shares are expected to begin trading on The Nasdaq Global Market on April 23, 2021 under the symbol "IMPL." The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Impel, are expected to be $80.0 million. In addition, Impel has granted the underwriters a 30-day option to purchase up to an additional 800,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions. The offering is expected to close on April 27, 2021, subject to the satisfaction of customary closing conditions.

    Cowen and Guggenheim Securities are acting as joint bookrunning managers for the proposed offering. Wedbush PacGrow is acting as lead manager.

    A registration statement relating to these securities has been filed with the Securities and Exchange Commission and became effective on April 22, 2021. The offering is being made only by means of a prospectus. A copy of the final prospectus relating to the offering, when available, may be obtained from: Cowen and Company, LLC, c/o Broadridge Financial Solutions, Attn: Prospectus Department, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at (833) 297-2926 or by email at PostSaleManualR; or Guggenheim Securities, LLC Attention: Equity Syndicate Department, 330 Madison Avenue, New York, NY 10017 or by telephone at (212) 518-9544, or by email at .

    This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

    About Impel NeuroPharma:

    Impel NeuroPharma, Inc. is a late-stage pharmaceutical company focused on utilizing its proprietary technology to develop and commercialize transformative therapies for people suffering from diseases with high unmet needs, with an initial focus on diseases of the CNS. The Company's strategy is to rapidly advance its product candidate pipeline that pairs its proprietary Precision Olfactory Delivery (POD®) system with well-established therapeutics, including TRUDHESA™ for the acute treatment of migraine, INP105 for the acute treatment of agitation and aggression in patients with autism, and INP107 for OFF episodes in Parkinson's disease.

    Contact

    Investor Relations:

    Christina Tartaglia

    Stern Investor Relations

    Phone: (1) 212-362-1200

    Email: 

    Media Relations:

    Melyssa Weible

    Elixir Health Public Relations

    Phone: (1) 201-723-5805

    Email: 

     



    Primary Logo

    View Full Article Hide Full Article
View All Impel NeuroPharma Inc. News